Developer docs
API playgroundTry for free, no card

Search company profiles

Inspira Technologies

Full company profile

uuid00009e1

Namestring
Inspira Technologies
Legal namestring
Inspira-Technologies OXY B.H.N. LTD.
Company typeenum
Public
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRa'anana, Israel
HQ citystring
Ra'anana
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
extracorporeal oxygenation systems, acute respiratory support devices, continuous blood monitoring sensors, cardiopulmonary bypass equipment, additively manufactured electronics
Industry3 codes
PRIMARYHLAHAGAC
Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAGAG
Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Industrial and Commercial Fan and Blower and Air Purification Equipment Manufacturing333413
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1Capital Equipment Sales
TypeHardware Sales
Description

One-time sale of INSPIRA ART100 and ART500 extracorporeal oxygenation systems to hospitals and medical centers, supplemented by installation, training, and warranty.

quantumzeitgeist.com
2Recurring Consumables and Disposables
TypeSubscription Recurring
Description

Recurring revenue from cartridges, sensors, and single-use disposables used per patient treatment, driving a razor/blade model attached to installed ART100/ART500 bases.

quantumzeitgeist.com
3AME Platform and Devices
TypeHardware Sales
Description

Sales of additively manufactured electronics (AME) platforms and printed electronic devices for medical, defense, and quantum sensing applications, with associated consumables.

stocktitan.net
4Quantum-Enabled AI Services
TypeManaged Services
Description

Emerging revenue stream from quantum computing access, AI-driven blood analytics, and data services powered by the Qarakal Quantum partnership.

medicalbuyer.co.in
5Strategic Equity Placements
TypeLicensing Royalties
Description

Capital raised through registered direct offerings and private placements with H.C. Wainwright and Alliance Global Partners acting as placement agents.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
Pricing details1 tier
1Quote-based capital purchase plus recurring consumables
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Pricing is custom per hospital and not publicly disclosed; contract values range from hundreds of thousands to over half a million dollars for initial system purchases, with recurring consumable revenue layered on top.

pulse2.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1INSPIRA ART100
Description

Gen 1 FDA 510(k) cleared (K232788) extracorporeal blood oxygenation system for Cardio-Pulmonary Bypass, integrating the HYLA 1 Blood Sensor.

inspira-technologies.com
+6 more records
Core offering1 text field

Inspira Technologies develops and sells extracorporeal blood oxygenation systems for acute respiratory support, headlined by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) and the next-generation INSPIRA ART500 built around proprietary VORTX Orbital Blood Oxygenation. The systems are paired with HYLA AI-powered continuous blood sensors, plug-and-play disposable cartridges, and a convertible dual-lumen cannula, generating both capital equipment sales and recurring consumable revenue from hospital ICUs and academic medical centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • $49.5 million in binding purchase orders across ART and AME products
+3 more records
Product overview1 text field

Inspira Technologies operates a platform-plus-modules medical-device portfolio for acute respiratory support and extracorporeal blood oxygenation, anchored by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) core system with its integrated HYLA 1 Blood Sensor, and the next-generation INSPIRA ART500 (Gen 2) built around the proprietary VORTX Orbital Blood Oxygenation technology and HYLA 2 continuous blood sensor. The HYLA sensors function as AI-powered monitoring modules that feed decision-making data into an algorithm-enhanced control unit with process automation (auto-priming and hemoprotective flow regulation). Building on this core, the company has introduced development-stage offerings such as the INSPIRA Cardi-ART device for cardiac-arrest oxygenation, signed a term sheet for an AI-powered liquid biopsy diagnostics platform, and — following the acquisition of Nano Dimension's Additively Manufactured Electronics (AME) platform and rebrand to QTREX Quantum — added a parallel QTREX AME platform business targeting quantum computing connectivity, with deployments to U.S. defense, top-10 U.S. enterprise, and academic customers. The Bites AI platform is embedded across the medical systems as an AI layer for training, operational efficiency, and customer support.

Product and service1 record
1INSPIRA ART100
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Acquired Nano Dimension's Additively Manufactured Electronics (AME) platform and associated assets, including a portfolio of printed-electronics patents and $200M+ of cumulative development investment. Inspira is integrating AME capabilities across its medical and quantum sensor roadmap.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint development partnership to connect Inspira's HYLA blood sensor platform with Qarakal's quantum computing infrastructure, enabling advanced AI analytics on blood data. Underpins Inspira's quantum-computing pivot and exposure to the $72B projected quantum market by 2035.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

U.S. distribution and clinical sales partner for Inspira's ART platform, providing field coverage of American hospital systems and supporting purchase orders such as the NYU Langone Health deployment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic alliance focused on AI, supporting the development of HYLA blood sensor analytics and Inspira's broader artificial intelligence roadmap.

5Terumo Cardiovascular
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

OEM agreement with Terumo Cardiovascular to integrate Inspira's extracorporeal oxygenation technology with Terumo's cardiovascular portfolio, expanding access to global hospital customers.

quantumzeitgeist.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Central American distribution partner supporting Inspira's regional sales of ART and AME products across hospital customers.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

European distribution partner extending Inspira's reach across EU hospital systems for extracorporeal oxygenation and AME offerings.

Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Clinical trials partner supporting execution of Inspira's clinical studies for the ART100/ART500 extracorporeal platform.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Production partner providing manufacturing capacity and supply chain expertise for Inspira's medical device production line.

Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration partner developing bio-electronic treatment technologies complementary to Inspira's extracorporeal platform.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Clinical collaboration partner and customer site supporting Inspira's technology development, clinical studies, and adoption within a leading Israeli academic medical center.

Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Clinical partner and customer site where the first patient was treated with Inspira's extracorporeal oxygenation technology.

Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Collaboration partner supporting perfusion-related clinical and commercial activities for Inspira's extracorporeal platform.

14Ben-Gurion University
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Academic research partner supporting R&D and clinical studies tied to Inspira's blood sensing and oxygenation programs.

globenewswire.com
Strategic tierSupportingTypeTechnology or Integration
Description

Technology partner providing software engineering and product development support for Inspira's digital and AI platforms.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medtech incumbent with a broad cardiac and respiratory support portfolio (including ECMO and perfusion systems). Comparable as the established scale player Inspira is targeting in the extracorporeal blood oxygenation market, but Medtronic operates across many other device categories rather than specializing in awake extracorporeal oxygenation.

TypeDirect peer
Description

Direct competitor in extracorporeal life support and perfusion through its Maquet/Cardiohelp ECMO and heart-lung machine lines. Comparable as a leading hospital supplier of oxygenation and cardiopulmonary support equipment, competing for the same ICU and cardiac surgery customer segment as the INSPIRA ART100/ART500.

TypeDirect peer
Description

Direct peer in cardiopulmonary bypass and extracorporeal circulation through its heart-lung machine and oxygenator portfolio. Comparable in addressing the same cardiac surgery and perfusion market that Inspira's ART100/ART500 targets, with overlapping hospital customers and regulatory pathways.

4Terumo Cardiovascular
TypeDirect peer
Description

Existing OEM partner of Inspira and direct peer in oxygenators, perfusion circuits, and cardiovascular surgical devices. Comparable as both a commercial channel for Inspira's technology and a competing supplier of integrated cardiovascular solutions to the same global hospital customer base.

TypeDirect peer
Description

Specialist in extracorporeal lung and heart assist therapies (iLA, ECCO2R) acquired by Fresenius. Comparable as a focused player in minimally invasive and extracorporeal respiratory/circulatory support, directly competing with Inspira's positioning in awake and non-invasive oxygenation.

TypeDirect peer
Description

Manufacturer of dialysis, oxygenator, and ECMO disposables. Comparable as a supplier of oxygenation and perfusion consumables to hospitals, with overlapping product economics (capital + consumables) similar to Inspira's razor/blade model.

7Abbott (CentriMag)
TypeBroad incumbent
Description

Broader medtech incumbent with a CentriMag and ECMO/perfusion presence. Comparable as a major cardiac support supplier addressing overlapping ICU and surgical customers, though Abbott's portfolio extends well beyond extracorporeal oxygenation.

TypeBroad incumbent
Description

J&J-owned circulatory and respiratory support specialist (Impella, plus legacy ECMO programs). Comparable as a higher-resource medtech player building next-generation support technologies in adjacent cardiac and respiratory care segments that Inspira targets.

TypeEmerging player
Description

Early-commercial-stage company developing extracorporeal CO2 removal and lung support systems (Hemolung). Comparable as a focused emerging competitor in extracorporeal respiratory support, with similar technology profile and clinical use cases to Inspira's VORTX/ART platform.

TypeOthers
Description

Seller of the AME platform Inspira acquired in April 2026, and a 3D-printed electronics specialist. Comparable as the originator of the AME business Inspira is now operating, providing a public-market reference point for the AME/quantum connectivity vertical Inspira is pivoting into.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inspira Technologies

Inspira Technologies firmographics

Firmographics
Name
Inspira Technologies
Legal name
Inspira-Technologies OXY B.H.N. LTD.
Website
https://inspira-technologies.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Inspira Technologies industry classification

Industry
Product category
Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Industrial and Commercial Fan and Blower and Air Purification Equipment Manufacturing (333413)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAGAC
Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAGAG
Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Extracorporeal oxygenation systems
  • Acute respiratory support devices
  • Continuous blood monitoring sensors
  • Cardiopulmonary bypass equipment
  • Additively manufactured electronics

Where Inspira Technologies is headquartered

Location

Headquarters

HQ city
Ra'anana
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Inspira Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

  1. Capital Equipment Sales: One-time sale of INSPIRA ART100 and ART500 extracorporeal oxygenation systems to hospitals and medical centers, supplemented by installation, training, and warranty.
  2. Recurring Consumables and Disposables: Recurring revenue from cartridges, sensors, and single-use disposables used per patient treatment, driving a razor/blade model attached to installed ART100/ART500 bases.
  3. AME Platform and Devices: Sales of additively manufactured electronics (AME) platforms and printed electronic devices for medical, defense, and quantum sensing applications, with associated consumables.
  4. Quantum-Enabled AI Services: Emerging revenue stream from quantum computing access, AI-driven blood analytics, and data services powered by the Qarakal Quantum partnership.
  5. Strategic Equity Placements: Capital raised through registered direct offerings and private placements with H.C. Wainwright and Alliance Global Partners acting as placement agents.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractQuote-based capital purchase plus recurring consumables

Go-to-market motion4 records

Distribution channels6 records

Marketing channels6 records

Inspira Technologies product offering

Product offering

Core offering

Inspira Technologies develops and sells extracorporeal blood oxygenation systems for acute respiratory support, headlined by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) and the next-generation INSPIRA ART500 built around proprietary VORTX Orbital Blood Oxygenation. The systems are paired with HYLA AI-powered continuous blood sensors, plug-and-play disposable cartridges, and a convertible dual-lumen cannula, generating both capital equipment sales and recurring consumable revenue from hospital ICUs and academic medical centers.

Product overview

Inspira Technologies operates a platform-plus-modules medical-device portfolio for acute respiratory support and extracorporeal blood oxygenation, anchored by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) core system with its integrated HYLA 1 Blood Sensor, and the next-generation INSPIRA ART500 (Gen 2) built around the proprietary VORTX Orbital Blood Oxygenation technology and HYLA 2 continuous blood sensor. The HYLA sensors function as AI-powered monitoring modules that feed decision-making data into an algorithm-enhanced control unit with process automation (auto-priming and hemoprotective flow regulation). Building on this core, the company has introduced development-stage offerings such as the INSPIRA Cardi-ART device for cardiac-arrest oxygenation, signed a term sheet for an AI-powered liquid biopsy diagnostics platform, and — following the acquisition of Nano Dimension's Additively Manufactured Electronics (AME) platform and rebrand to QTREX Quantum — added a parallel QTREX AME platform business targeting quantum computing connectivity, with deployments to U.S. defense, top-10 U.S. enterprise, and academic customers. The Bites AI platform is embedded across the medical systems as an AI layer for training, operational efficiency, and customer support.

Differentiator

Problem solved

Functional benefit

Brands

  • INSPIRA ART100: Gen 1 FDA 510(k) cleared (K232788) extracorporeal blood oxygenation system for Cardio-Pulmonary Bypass, integrating the HYLA 1 Blood Sensor.
  • INSPIRA ART500
  • HYLA
  • VORTX
  • QTREX AME Platform
  • ALICE
  • INSPIRA Cardi-ART

Products and services

  • INSPIRA ART100

Quantifiable outcome

  • $49.5 million in binding purchase orders across ART and AME products
  • +3 more outcomes

Companies that use Inspira Technologies

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles3 records

Inspira Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature8 records

Inspira Technologies partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered flagship, core and supporting.

  • Nano DimensionflagshipStrategic or Co-development PartnerAcquired Nano Dimension's Additively Manufactured Electronics (AME) platform and associated assets, including a portfolio of printed-electronics patents and $200M+ of cumulative development investment. Inspira is integrating AME capabilities across its medical and quantum sensor roadmap.
  • Qarakal QuantumflagshipStrategic or Co-development PartnerJoint development partnership to connect Inspira's HYLA blood sensor platform with Qarakal's quantum computing infrastructure, enabling advanced AI analytics on blood data. Underpins Inspira's quantum-computing pivot and exposure to the $72B projected quantum market by 2035.
  • Glo-Med NetworkscoreChannel Partner/ Reseller/ DistributorU.S. distribution and clinical sales partner for Inspira's ART platform, providing field coverage of American hospital systems and supporting purchase orders such as the NYU Langone Health deployment.
  • Bites Learning Ltd.coreStrategic or Co-development PartnerStrategic alliance focused on AI, supporting the development of HYLA blood sensor analytics and Inspira's broader artificial intelligence roadmap.
  • Terumo CardiovascularcoreOEM/ Whitelabel/ Licensing PartnerOEM agreement with Terumo Cardiovascular to integrate Inspira's extracorporeal oxygenation technology with Terumo's cardiovascular portfolio, expanding access to global hospital customers.
  • CIO MED GROUPcoreChannel Partner/ Reseller/ DistributorCentral American distribution partner supporting Inspira's regional sales of ART and AME products across hospital customers.
  • Waas GroupcoreChannel Partner/ Reseller/ DistributorEuropean distribution partner extending Inspira's reach across EU hospital systems for extracorporeal oxygenation and AME offerings.
  • InnovimedsupportingImplementation/ SI/ Consulting PartnerClinical trials partner supporting execution of Inspira's clinical studies for the ART100/ART500 extracorporeal platform.
  • Zriha MedicalcoreOEM/ Whitelabel/ Licensing PartnerProduction partner providing manufacturing capacity and supply chain expertise for Inspira's medical device production line.
  • EnnocuresupportingTechnology or IntegrationCollaboration partner developing bio-electronic treatment technologies complementary to Inspira's extracorporeal platform.
  • Sheba Medical CentercoreImplementation/ SI/ Consulting PartnerClinical collaboration partner and customer site supporting Inspira's technology development, clinical studies, and adoption within a leading Israeli academic medical center.
  • Westchester Medical CentersupportingImplementation/ SI/ Consulting PartnerClinical partner and customer site where the first patient was treated with Inspira's extracorporeal oxygenation technology.
  • Perfusion Solution Inc.supportingImplementation/ SI/ Consulting PartnerCollaboration partner supporting perfusion-related clinical and commercial activities for Inspira's extracorporeal platform.
  • Ben-Gurion UniversitysupportingImplementation/ SI/ Consulting PartnerAcademic research partner supporting R&D and clinical studies tied to Inspira's blood sensing and oxygenation programs.
  • GlobalLogicsupportingTechnology or IntegrationTechnology partner providing software engineering and product development support for Inspira's digital and AI platforms.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Inspira Technologies competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Global medtech incumbent with a broad cardiac and respiratory support portfolio (including ECMO and perfusion systems). Comparable as the established scale player Inspira is targeting in the extracorporeal blood oxygenation market, but Medtronic operates across many other device categories rather than specializing in awake extracorporeal oxygenation.
  • Abbott (CentriMag): Broader medtech incumbent with a CentriMag and ECMO/perfusion presence. Comparable as a major cardiac support supplier addressing overlapping ICU and surgical customers, though Abbott's portfolio extends well beyond extracorporeal oxygenation.
  • Abiomed (Johnson & Johnson): J&J-owned circulatory and respiratory support specialist (Impella, plus legacy ECMO programs). Comparable as a higher-resource medtech player building next-generation support technologies in adjacent cardiac and respiratory care segments that Inspira targets.

Direct peers

  • Getinge (Maquet): Direct competitor in extracorporeal life support and perfusion through its Maquet/Cardiohelp ECMO and heart-lung machine lines. Comparable as a leading hospital supplier of oxygenation and cardiopulmonary support equipment, competing for the same ICU and cardiac surgery customer segment as the INSPIRA ART100/ART500.
  • LivaNova: Direct peer in cardiopulmonary bypass and extracorporeal circulation through its heart-lung machine and oxygenator portfolio. Comparable in addressing the same cardiac surgery and perfusion market that Inspira's ART100/ART500 targets, with overlapping hospital customers and regulatory pathways.
  • Terumo Cardiovascular: Existing OEM partner of Inspira and direct peer in oxygenators, perfusion circuits, and cardiovascular surgical devices. Comparable as both a commercial channel for Inspira's technology and a competing supplier of integrated cardiovascular solutions to the same global hospital customer base.
  • Xenios (Fresenius Medical Care): Specialist in extracorporeal lung and heart assist therapies (iLA, ECCO2R) acquired by Fresenius. Comparable as a focused player in minimally invasive and extracorporeal respiratory/circulatory support, directly competing with Inspira's positioning in awake and non-invasive oxygenation.
  • Nipro Medical: Manufacturer of dialysis, oxygenator, and ECMO disposables. Comparable as a supplier of oxygenation and perfusion consumables to hospitals, with overlapping product economics (capital + consumables) similar to Inspira's razor/blade model.

Emerging players

  • ALung Technologies: Early-commercial-stage company developing extracorporeal CO2 removal and lung support systems (Hemolung). Comparable as a focused emerging competitor in extracorporeal respiratory support, with similar technology profile and clinical use cases to Inspira's VORTX/ART platform.

Others

  • Nano Dimension: Seller of the AME platform Inspira acquired in April 2026, and a 3D-printed electronics specialist. Comparable as the originator of the AME business Inspira is now operating, providing a public-market reference point for the AME/quantum connectivity vertical Inspira is pivoting into.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Inspira Technologies social profiles

Digital presence

Inspira Technologies compliance and trust

Trust signal

Compliance3 records

Inspira Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inspira Technologies leadership team

Management profile

Number of profiles

Profiles14 records

Inspira Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Inspira Technologies funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inspira Technologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inspira Technologies

What does Inspira Technologies do?

Inspira Technologies develops and sells extracorporeal blood oxygenation systems for acute respiratory support, headlined by the FDA 510(k)-cleared INSPIRA ART100 (Gen 1) and the next-generation INSPIRA ART500 built around proprietary VORTX Orbital Blood Oxygenation. The systems are paired with HYLA AI-powered continuous blood sensors, plug-and-play disposable cartridges, and a convertible dual-lumen cannula, generating both capital equipment sales and recurring consumable revenue from hospital ICUs and academic medical centers.

Is Inspira Technologies a public or private company?

Inspira Technologies is a public company. It is classified as public and is currently operating.

When was Inspira Technologies founded?

Inspira Technologies was founded in 2018. It employs 51 to 100 people.

Where is Inspira Technologies based?

Inspira Technologies is headquartered in Ra'anana, Israel, in the Middle East region.

How does Inspira Technologies make money?

Five revenue lines are on record. Capital Equipment Sales are the primary driver. The others are recurring Consumables and Disposables, AME Platform and Devices, quantum-Enabled AI Services and strategic Equity Placements.

Who are Inspira Technologies's main competitors?

Broad incumbents on record are Medtronic, Abbott (CentriMag) and Abiomed (Johnson & Johnson). Direct peers are Getinge (Maquet), LivaNova, Terumo Cardiovascular, Xenios (Fresenius Medical Care) and Nipro Medical. ALung Technologies is listed as an emerging player. Nano Dimension is listed as an others.

Does Inspira Technologies have an API?

No public API is recorded for Inspira Technologies.

What industry is Inspira Technologies in?

Inspira Technologies's product category is Medical Devices. Its primary akta.pro industry code is HLAHAGAC, Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home), with a secondary code of HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 339112 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketBeatInspira Technologies OXY B.H.N. (NASDAQ:QTEX) CEO Buys $20,998.57 in StockInspira Technologies CEO Dagi Ben-Noon bought 14,093 shares on October 13th at $1.49 each, totaling $20,998.57. The stock rose 1.6% to $1.60, and the company has a consensus "Sell" rating from analysts.American Banking and Market NewsInsider Buying: Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) CEO Purchases $30,362.27 in StockInspira Technologies CEO Dagi Ben-Noon bought 18,181 shares on October 9th at $1.67 each, totaling $30,362.27. The purchase raised his direct ownership by 0.50% to 3,664,314 shares. The company reported a quarterly loss of $0.07 per share and a consensus "Sell" rating.MarketBeatInsider Buying: Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) CEO Buys $30,362.27 in StockInspira Technologies CEO Dagi Ben-Noon bought 18,181 shares on October 9th at $1.67 each, totaling $30,362.27. The purchase increased his stake by 0.50% to 3,664,314 shares. The stock traded up $0.07 to $1.76, with analysts rating it a Sell.American Banking and Market NewsPromising Penny Stocks To Watch Today – October 4thMarketBeat's stock screener identified seven penny stocks with the highest dollar trading volume in recent days: Alpha Modus, Cycurion, Inspira Technologies OXY B.H.N., XIAO-I, Flux Power, and Eos Energy Enterprises. The companies span blank check, medical device, AI software, energy storage, and battery solutions. Penny stocks are highly speculative and volatile.Markets DailyPenny Stocks To Research – October 3rdMarketBeat's stock screener identified seven penny stocks with the highest dollar trading volume in recent days: Alpha Modus, Cycurion, Inspira Technologies OXY B.H.N., XIAO-I, Flux Power, and Eos Energy Enterprises. The companies span blank check, medical devices, AI software, energy storage, and battery systems.Ticker ReportInspira Technologies OXY B.H.N. (NASDAQ:QTEX) Cut to “Sell” at Wall Street ZenWall Street Zen downgraded Inspira Technologies OXY B.H.N. shares from a hold to a sell rating, while Weiss Ratings also initiated coverage with a "sell (e+)" rating. The company recently approved a share buyback plan authorizing the repurchase of up to 5.6% of its stock.Stock TitanInspira to trade as QTREX Quantum under QTEXInspira Technologies Oxy B.H.N. Ltd. will begin trading under the new Nasdaq ticker symbol "QTEX" on May 20, 2026, following a corporate name change to QTREX Quantum Ltd. The rebranding reflects the company's strategic pivot toward its Additively Manufactured Electronics (AME) technology platform, which it plans to apply to quantum computing connectivity infrastructure inside dilution cryostats. Existing shareholders require no action, and the company's warrants will trade under the symbol "QTEXW."Pulse 2.0Inspira Technologies: $580,000 NYU Langone Purchase Order For FDA-Cleared ART100 SystemsInspira Technologies announced that NYU Langone Health issued a $580,000 commercial purchase order for the company's FDA-cleared ART100 extracorporeal blood circulation systems following a multi-patient clinical evaluation involving more than 30 patients across cardiopulmonary and surgical cases. The systems are scheduled for immediate fulfillment, with NYU Langone transitioning from hospital-based evaluation to commercial procurement. The company stated it is continuing discussions with additional U.S. and international hospital systems evaluating extracorporeal support technologies.Stock TitanInspira CEO outlines quantum, AME and medical planInspira Technologies CEO Dagi Ben-Noon issued a letter to shareholders outlining the company's three-part strategic plan: an Additively Manufactured Electronics (AME) platform targeting quantum computing connectivity, a quantum connectivity program addressing cryogenic wiring bottlenecks, and monetization of the legacy medical business. The company has signed a joint development agreement with Qarakal Quantum Ltd. to validate its quantum connectivity architecture and has already deployed a commercial AME system at a Tier-1 U.S. defense customer while commencing implementation with one of the Magnificent Seven technology companies, generating over $1 million in recent transactions. Shareholders have approved changing the company's name to QTREX Quantum Ltd. as it positions to become a foundational connectivity layer for the quantum computing industry.GlobeNewswireInspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation PlanInspira Technologies CEO Dagi Ben-Noon issued a shareholder letter outlining a three-track strategy: a commercially active AME platform, a quantum connectivity program, and a medical business being monetized. The company expects a revenue ramp from AME sales and recurring revenues, with a potential medical transaction by Q3 2026. It also plans to submit its HYLA platform for FDA clearance.